[{"orgOrder":0,"company":"TFS International AB","sponsor":"Oncomatryx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"OMTX705","moa":"FAP-alpha\/Tubulin","graph1":"Oncology","graph2":"IND Enabling","graph3":"TFS International AB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TFS International AB \/ Oncomatryx","highestDevelopmentStatusID":"5","companyTruncated":"TFS International AB \/ Oncomatryx"}]

Find Clinical Drug Pipeline Developments & Deals by TFS International AB

Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : The collaboration aims to advance the clinical development of OMTX705 in patients with advanced or metastatic pancreatic adenocarcinoma.

                          Product Name : OMTX705

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          May 06, 2025

                          Lead Product(s) : OMTX705

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Oncomatryx

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank